文献速递中毒与环境急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

阿片类药物剂量递减后过量或心理健康危机的长期风险

Long-term Risk of Overdose or Mental Health Crisis After Opioid Dose Tapering.
PubMed 文献 · JAMA Netw Open · 2022-06-01
一句话结论阿片剂量递减后12至24个月,过量或戒断及心理健康危机的发生率仍分别升高57%和52%。

这项暴露交叉队列研究利用OptumLabs数据库,纳入2008至2017年稳定日剂量≥50吗啡毫克当量、随后进行阿片剂量递减的美国成人,共19377例患者、21515次递减事件。递减定义为7个月随访期内6个重叠60天窗口中任一日均剂量相对降低≥15%。与递减前相比,递减后12至24个月因过量或戒断就诊的调整发生率比为1.57(95%CI 1.42-1.74),心理健康危机为1.52(95%CI 1.35-1.71)。作者认为,阿片递减与递减启动后长达2年的过量、戒断和心理健康危机发生率升高相关。

要点

  • 阿片递减后12至24个月,因过量或戒断就诊的调整发生率比为1.57(95%CI 1.42-1.74),高于递减前。
  • 同期心理健康危机(抑郁、焦虑或自杀未遂)的调整发生率比为1.52(95%CI 1.35-1.71),同样高于递减前。
  • 递减定义为7个月随访期内6个重叠60天窗口中任一日均剂量相对降低≥15%。
  • 研究纳入稳定日剂量≥50吗啡毫克当量后递减、且递减启动12个月后至少随访1个月的美国成人。
  • 作者认为,递减与递减启动后长达2年的过量、戒断和心理健康危机发生率升高相关。

适用人群与场景

  • 美国成人,2008至2017年期间在12个月基线稳定日剂量≥50吗啡毫克当量后接受阿片剂量递减,且在递减启动12个月后的诱导后期至少有1个月长期随访。
  • 数据来自OptumLabs数据仓库,包含商业保险和Medicare Advantage参保者的去标识化医疗与药房理赔及参保记录,覆盖美国不同年龄、种族、族裔和地理区域。

诊断标准与关键阈值

  • 阿片剂量递减定义:在稳定基线期后的7个月随访期内,6个重叠60天窗口中任一日均日剂量相对降低≥15%。

研究设计与关键结果

  • 研究设计:采用暴露交叉分析的队列研究,数据来自OptumLabs数据仓库,分析时间为2021年10月至2022年4月。
  • 样本:19377例患者共21515次递减事件,每次事件诱导后期平均(SD)随访9.1(2.7)个月(中位数[IQR]10[8-11]个月)。
  • 人群特征:平均(SD)年龄56.9(11.2)岁,女性11581例(53.8%),商业保险8217例(38.2%),其余为Medicare Advantage。
  • 主要终点:在条件负二项回归分析中,诱导后期与递减前相比,过量或戒断的调整发生率比为1.57(95%CI 1.42-1.74)。
  • 主要终点:心理健康危机的调整发生率比为1.52(95%CI 1.35-1.71)。
  • 结局定义:因药物过量或戒断以及心理健康危机(抑郁、焦虑或自杀未遂)的急诊或住院就诊;结局计数在递减前和诱导后期(递减启动后12至24个月)评估。

证据类型、等级与局限

  • 证据类型:队列研究(暴露交叉分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,阿片递减与递减启动后长达2年的过量、戒断和心理健康危机发生率升高相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Patients prescribed long-term opioid therapy are increasingly undergoing dose tapering. Recent studies suggest that tapering is associated with short-term risks of substance misuse, overdose, and mental health crisis, although lower opioid dose could reduce risks of adverse events over the longer term.

OBJECTIVE: To assess the longer-term risks of overdose or mental health crisis associated with opioid dose tapering.

DESIGN, SETTING, AND PARTICIPANTS: This is a cohort study using an exposure-crossover analysis. Data were obtained from the OptumLabs Data Warehouse, which includes deidentified medical and pharmacy claims and enrollment records for commercial insurance and Medicare Advantage enrollees, representing a diverse mixture of ages, races, ethnicities, and geographical regions across the US. Participants were US adults who underwent opioid dose tapering from 2008 to 2017 after a 12-month baseline period of stable daily dosing of 50 morphine milligram equivalents or higher and who had at least 1 month of long-term follow-up during a postinduction period beginning 12 months after taper initiation. Data analysis was performed from October 2021 to April 2022.

EXPOSURES: Opioid tapering, defined as 15% or more relative reduction in mean daily dose during any of 6 overlapping 60-day windows within a 7-month follow-up period after the stable baseline period.

MAIN OUTCOMES AND MEASURES: Emergency or hospital encounters for drug overdose or withdrawal and mental health crisis (depression, anxiety, or suicide attempt). Outcome counts were assessed in pretaper and postinduction periods (from 12 to 24 months after taper initiation).

RESULTS: The study included 21 515 tapering events among 19 377 patients with a mean (SD) of 9.1 (2.7) months of postinduction follow-up per event (median [IQR], 10 [8-11] months). Patients had a mean (SD) age of 56.9 (11.2) years, 11 581 (53.8%) were female, and 8217 (38.2%) had commercial insurance (vs Medicare Advantage). In conditional negative binomial regression analyses, adjusted incidence rate ratios for the postinduction period compared with the pretaper period were 1.57 (95% CI, 1.42-1.74) for overdose or withdrawal and 1.52 (95% CI, 1.35-1.71) for mental health crisis.

CONCLUSIONS AND RELEVANCE: These findings suggest that opioid tapering was associated with increased rates of overdose, withdrawal, and mental health crisis extending up to 2 years after taper initiation.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Fenton JJ, Magnan E, Tseregounis IE, et al. Long-term Risk of Overdose or Mental Health Crisis After Opioid Dose Tapering. JAMA Netw Open. 2022. PMID: 35696163. doi:10.1001/jamanetworkopen.2022.16726

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。